Ashland (ASH) investor relations material

Strategic progress and innovation pipeline

• Significant progress in validating and commercializing new technologies, focusing on scalable, high-value opportunities across pharma, personal care, and coatings.

• Portfolio transformation is complete; current focus is on executing, globalizing, innovating, and disciplined investing to drive organic growth and profitability.

• Innovation strategy centers on performance superiority, cost competitiveness, sustainability, and strategic customer fit, with over 52 patents filed and a culture of curiosity accelerating technology development.

• Third-party validation confirmed a $9B addressable market, with 40+ projects and seven scalable platforms advancing from ideation to commercialization.

• Multiple levers for growth include productivity, cost savings, and disciplined investment following market traction.

Key technology platforms and commercialization

• Transformed Vegetable Oil (TVO) platform has launched six products, expanded into multiple markets, and filed 33 patents; now includes polymeric TVO for broader applications.

• Multifunctional starch platform is launching Stabileze S for skincare in 2026 and expanding into hair care in 2027, with global regulatory clearance and strong customer feedback.

• Super Wetter platform is replacing PFAS and silicones, with tunable polymers for coatings, crop care, and haircare; five to seven grades commercialized using green manufacturing.

• Sugarcane bagasse upcycling converts waste into cost-effective, high-performance cellulosic materials, offering over 50% cost reduction and four patents filed.

• Seven scalable, patent-protected technology platforms validated and launched or nearing launch across major end markets.

Business segment highlights

• Personal Care: Launching Softhance TVO (hair conditioning, $850M market) and Stabileze S (skincare, $300M market); robust pipeline includes biofunctional actives and superwetting agents.

• Life Sciences: Focused on bioprocessing, injectables, and oral biologics/GLP-1s, opening $1.6B in new markets and achieving rapid commercial traction with multimillion-dollar orders.

• Specialty Additives: TVO TiO2 spacer reduces paint costs and carbon footprint, with >$1B market potential; TVO radiation cure delivers fast, durable coatings for batteries and industrial applications.

• Bioresorbable polymers platform achieved 400% sales growth in five years, with dual manufacturing sites and strong pharma adoption.

• Oral biologics and GLP-1 delivery market exceeds $100B by 2030, with launch of permexa permeation enhancer and over 40 engaged companies.